Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720278 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 526
- Enrollment target
NCT00720278 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 526 participants.
The verdict
NCT00720278, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 526 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if two allergy medications are more effective than placebo.
Interventions
- DRUG Placebo
- DRUG 0.15% azelastine hydrochloride 1644 mcg daily
- DRUG 0.1% azelastine hydrochloride 1096 mcg daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 526 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720278
The ClinicalTrials.gov registry entry for NCT00720278 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 526 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meda Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00720278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720278 about?
NCT00720278 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies". The purpose of this study was to determine if two allergy medications are more effective than placebo.
What is the current status of trial NCT00720278?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 526 participants. The study started on 2007-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00720278?
The interventions under investigation include: Placebo (DRUG), 0.15% azelastine hydrochloride 1644 mcg daily (DRUG), 0.1% azelastine hydrochloride 1096 mcg daily (DRUG).
Who is sponsoring clinical trial NCT00720278?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.